A nationwide cohort of 257 adult patients in first remission (CR1) from AML associated with an IDH2 mutation (IDH2m) undergoing allogeneic transplant during the period 2013–2019 in the United States had rates of relapse and survival three years after transplantation of 24% and 71%, respectively. Here, IDH2 is linked to acute myeloid leukemia.